

Published in final edited form as:

Heart Rhythm. 2005 August ; 2(8): 804–806.

***In vivo* human demonstration of phase 2 reentry**

Charles Antzelevitch, PhD

From Masonic Medical Research Laboratory, Utica, New York.

The presence of a prominent notch in the action potential of ventricular epicardium but not endocardium gives rise to a transmural voltage gradient during ventricular activation that manifests as a late delta wave following the QRS or what is commonly referred to as a *J wave*¹ or *Osborn wave*. The J wave and elevated J point have been described in the ECG of animals and humans for more than five decades, since Osborn's observation in the early 1950s.² In humans, the appearance of a prominent J wave on the ECG is considered pathognomonic of hypothermia,³⁻⁶ hypercalcemia,^{7,8} or sudden death syndromes, including idiopathic ventricular fibrillation (VF),⁹ ischemia/reperfusion-induced VF,¹⁰ and the Brugada syndrome.¹¹ A distinct J wave is commonly observed in the ECG of some animal species, including baboons and dogs, under baseline conditions and is greatly amplified under hypothermic conditions.¹²⁻¹⁴ An elevated J point is commonly encountered in humans and some animal species under normal conditions.

A transmural gradient in the contribution of the transient outward current (I_{to}) is responsible for the transmural gradient in the magnitude of phase 1 and action potential notch, which in turn inscribes the J-wave or J-point elevation in the ECG.^{1,15-18}

The presence of a prominent I_{to} -mediated notch predisposes canine ventricular epicardium to all-or-none repolarization and phase 2 reentry. Under pathophysiologic conditions (e.g., ischemia, metabolic inhibition, genetic defects in *SCN5A*) and with some pharmacologic interventions (e.g., I_{Na} or I_{Ca} blockers or I_{K-ATP} activators), canine ventricular epicardium exhibits an accentuation of the notch leading to loss of the action potential dome secondary to a rebalancing of currents flowing at the end of phase 1 of the action potential. The dome fails to develop when the outward currents (principally I_{to}) overwhelm the inward currents (chiefly I_{Ca}), resulting in a remarkable (40–70%) abbreviation of the action potential. Loss of the action potential dome is seldom homogeneous. The action potential dome usually is abolished at some epicardial sites but not others, causing a marked dispersion of repolarization within the epicardium. Conduction of the action potential dome from sites at which it is maintained to sites at which it is abolished can cause local reexcitation of the preparation. This mechanism, termed *phase 2 reentry*, produces closely coupled extrasystolic beats capable of initiating circus movement reentry.¹⁹ It is termed phase 2 reentry because phase 2 (dome) of the action potential reenters to reexcite the myocardium.

Electrical heterogeneity has been shown to give rise to phase 2 reentry in canine epicardium exposed to (1) K^+ channel openers such as pinacidil²⁰; (2) sodium channel blockers such as flecainide²¹; (3) combined sodium and calcium channel block, as with terfenadine²²; (4) increased $[Ca^{2+}]_o$ ²³; (5) metabolic inhibition¹⁵; and (6) ischemic conditions.^{10,19} Block of I_{to} restores the action potential dome, thus restoring electrical homogeneity and abolishing reentrant activity in all cases.

Address reprint requests and correspondence: Dr. Charles Antzelevitch, Masonic Medical Research Laboratory, 2150 Bleecker Street, Utica, New York 13501. E-mail address: ca@mmrl.edu..

Supported by Grants HL47678 from the National Institutes of Health, American Heart Association, NYS Affiliate, and the Masons of New York State and Florida.

Accentuation of the epicardial action potential notch and/or loss of the action potential dome can appear in the ECG as an elevated J point, accentuated J wave, or ST-segment elevation, all manifestations of the pronounced transmural voltage gradient.

In this issue of *Heart Rhythm*, Thomsen et al²⁴ provide for the first time evidence supporting the hypothesis that a phase 2 reentrant mechanism underlies arrhythmic activity arising from the right ventricle, often the right ventricular outflow tract. The authors demonstrate J-point elevation, ST-segment elevation, and T-wave changes in the sinus beat preceding ventricular extrasystoles and/or nonsustained ventricular tachycardia in 15 of the 18 patients (83%) studied. Although indirect, the evidence is compatible with phase 2 reentry as the mechanism responsible for ventricular extrasystoles and nonsustained ventricular tachycardia in man, a mechanism previously described only in experimental models.

The mean coupling interval of the extrasystoles ranged from 300 to 505 ms, with half of the patients showing relatively long coupling intervals of 400 ms or longer. Although phase 2 reentrant beats are expected to manifest relatively short coupling intervals in the ECG, the initial phase 2 reentry often is buried and therefore concealed in the T wave of the preceding sinus beat.²² Under these conditions, only the second beat (first epicardial or intramural circus movement reentrant beat) is clearly discernible in the ECG, accounting for the longer apparent coupling interval for the phase 2 reentrant beat.²²

These characteristics of the J wave and ST segment have been linked to idiopathic ventricular fibrillation and the Brugada syndrome.²⁵⁻²⁸ The Brugada syndrome is characterized by ST-segment elevation (or exaggerated J wave) in the right precordial leads, leads V₁ to V₃ (unrelated to ischemia, electrolyte abnormalities, or structural heart disease), normal QT interval, and a high incidence of sudden cardiac death due to ventricular tachycardia or VF.²⁵

In experimental models of the Brugada syndrome, loss of the epicardial action potential dome is caused by an outward shift in the balance of currents active during the early phases of the action potential, principally I_{to} and I_{Ca}. Autonomic neurotransmitters such as acetylcholine facilitate loss of the action potential dome²⁹ by suppressing I_{Ca} and/or augmenting potassium current. Beta-adrenergic agonists restore the dome by augmenting I_{Ca}. Sodium channel blockers also facilitate loss of the canine right ventricular action potential dome via a negative shift in the voltage at which phase 1 begins.^{21,30} These findings are consistent with clinical reports of accentuation of ST-segment elevation in patients with Brugada syndrome following vagal maneuvers or administration of class I antiarrhythmic agents and of normalization of the ST-segment elevation following beta-adrenergic agents.^{1,31} The appearance of ST-segment elevation only in the right precordial leads in Brugada patients is consistent with the finding that loss of the action potential dome is encountered much more commonly in right vs left canine ventricular epicardium.^{15,32} The Brugada syndrome is a right ventricular disease because I_{to} density is intrinsically much greater in right vs left ventricular epicardium.³³ This observation is consistent with the finding by Thomsen et al that arrhythmic activity associated with J-point or ST-segment elevation generally arises from the right ventricle.

Because a prominent I_{to} is pivotal to this arrhythmogenic mechanism, agents that inhibit I_{to}, including quinidine, are effective in restoring the action potential dome, thus restoring electrical homogeneity and aborting all arrhythmic activity in experimental models of the Brugada syndrome³⁴ and in the clinic.³⁵⁻³⁷ Future studies might be directed at examining the effectiveness of quinidine or more specific I_{to} blockers, as they become available, on the extrasystolic activity characterized by Thomsen et al as a further test of the hypothesis that phase 2 reentry underlies this activity and as an alternative approach to therapy.

References

1. Yan GX, Antzelevitch C. Cellular basis for the electrocardiographic J wave. *Circulation* 1996;93:372–379. [PubMed: 8548912]
2. Osborn JJ. Experimental hypothermia: respiratory and blood pH changes in relation to cardiac function. *Am J Physiol* 1953;175:389–398. [PubMed: 13114420]
3. Clements SD, Hurst JW. Diagnostic value of ECG abnormalities observed in subjects accidentally exposed to cold. *Am J Cardiol* 1972;29:729–734. [PubMed: 5021504]
4. Thompson R, Rich J, Chmelik F, Nelson WL. Evolutionary changes in the electrocardiogram of severe progressive hypothermia. *J Electrocardiol* 1977;10:67–70. [PubMed: 833527]
5. Corbin LV, Scher AM. The canine heart as an electrocardiographic generator. Dependence on cardiac cell orientation. *Circ Res* 1977;41:58–67. [PubMed: 862144]
6. Eagle K. Images in clinical medicine. Osborn waves of hypothermia. *N Engl J Med* 1994;10:680.
7. Kraus F. Ueber die wirkung des kalziiums auf den kreislauf. *Dtsch Med Wochenschr* 1920;46:201–203.
8. Sridharan MR, Horan LG. Electrocardiographic J wave of hypercalcemia. *Am J Cardiol* 1984;54:672–673. [PubMed: 6475794]
9. Yan GX, Lankipalli RS, Burke JF, Musco S, Kowey PR. Ventricular repolarization components on the electrocardiogram: cellular basis and clinical significance. *J Am Coll Cardiol* 2003;42:401–409. [PubMed: 12906963]
10. Yan GX, Joshi A, Guo D, Hlaing T, Martin J, Xu X, Kowey PR. Phase 2 reentry as a trigger to initiate ventricular fibrillation during early acute myocardial ischemia. *Circulation* 2004;100:1036–1041. [PubMed: 15302777]
11. Antzelevitch, C.; Brugada, P.; Brugada, J.; Brugada, R. *The Brugada Syndrome: From Bench to Bedside*. Blackwell Futura; Oxford: 2005.
12. Hugo N, Dormehl IC, Van Gelder AL. A positive wave at the J-point of electrocardiograms of anaesthetized baboons. *J Med Primatol* 1988;17:347–352. [PubMed: 3221379]
13. West TC, Frederickson EL, Amory DW. Single fiber recording of the ventricular response to induced hypothermia in the anesthetized dog. Correlation with multicellular parameters. *Circ Res* 1959;7:880–888. [PubMed: 13844152]
14. Santos EM, Frederick KC. Electrocardiographic changes in the dog during hypothermia. *Am Heart J* 1957;55:415–420.
15. Antzelevitch, C.; Sicouri, S.; Lukas, A.; Di Diego, JM.; Nesterenko, VV.; Liu, DW.; Roubache, JF.; Zygmunt, AC.; Zhang, ZQ.; Iodice, A. Clinical implications of electrical heterogeneity in the heart: the electrophysiology and pharmacology of epicardial, M, and endocardial cells. In: Podrid, PJ.; Kowey, PR., editors. *Cardiac Arrhythmia: Mechanism, Diagnosis and Management*. William & Wilkins; Baltimore: 1995. p. 88-107.
16. Antzelevitch, C.; Sicouri, S.; Lukas, A.; Nesterenko, VV.; Liu, DW.; Di Diego, JM. Regional differences in the electrophysiology of ventricular cells: physiological and clinical implications. In: Zipes, DP.; Jalife, J., editors. *Cardiac Electrophysiology: From Cell to Bedside*. Second edition. WB Saunders; Philadelphia: 1994. p. 228-245.
17. Litovsky SH, Antzelevitch C. Transient outward current prominent in canine ventricular epicardium but not endocardium. *Circ Res* 1988;62:116–126. [PubMed: 2826039]
18. Liu DW, Gintant GA, Antzelevitch C. Ionic bases for electrophysiological distinctions among epicardial, midmyocardial, and endocardial myocytes from the free wall of the canine left ventricle. *Circ Res* 1993;72:671–687. [PubMed: 8431990]
19. Lukas A, Antzelevitch C. Phase 2 reentry as a mechanism of initiation of circus movement reentry in canine epicardium exposed to simulated ischemia. *Cardiovasc Res* 1996;32:593–603. [PubMed: 8881520]
20. Di Diego JM, Antzelevitch C. Pinacidil-induced electrical heterogeneity and extrasystolic activity in canine ventricular tissues. Does activation of ATP-regulated potassium current promote phase 2 reentry? *Circulation* 1993;88:1177–1189. [PubMed: 7689041]
21. Krishnan SC, Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? *Circulation* 1993;87:562–572. [PubMed: 8425300]

22. Fish JM, Antzelevitch C. Role of sodium and calcium channel block in unmasking the Brugada syndrome. *Heart Rhythm* 2004;1:210–217. [PubMed: 15851155]
23. Di Diego JM, Antzelevitch C. High $[Ca^{2+}]$ -induced electrical heterogeneity and extrasystolic activity in isolated canine ventricular epicardium. Phase 2 reentry. *Circulation* 1994;89:1839–1850. [PubMed: 7511994]
24. Thomsen PEB, Joergensen RM, Kanters JK, Jensen JT, Haarbo J, Hagemann A, Vestergaard A, Saermark K. Phase 2 reentry in man. *Heart Rhythm* 2005;2:797–803. [PubMed: 16051112]
25. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. *J Am Coll Cardiol* 1992;20:1391–1396. [PubMed: 1309182]
26. Aizawa Y, Tamura M, Chinushi M, Naitoh N, Uchiyama H, Kusano Y, Hosono H, Shibata A. Idiopathic ventricular fibrillation and bradycardia-dependent intraventricular block. *Am Heart J* 1993;126:1473–1474. [PubMed: 8249808]
27. Aizawa Y, Tamura M, Chinushi M, Niwano S, Kusano Y, Naitoh N, Shibata A, Tohjoh T, Ueda Y, Joho K. An attempt at electrical catheter ablation of the arrhythmogenic area in idiopathic ventricular fibrillation. *Am Heart J* 1992;123:257–260. [PubMed: 1729844]
28. Bjerregaard P, Gussak I, Kotar SI, Gessler JE. Recurrent syncope in a patient with prominent J-wave. *Am Heart J* 1994;127:1426–1430. [PubMed: 8172079]
29. Litovsky SH, Antzelevitch C. Differences in the electrophysiological response of canine ventricular subendocardium and subepicardium to acetylcholine and isoproterenol. A direct effect of acetylcholine in ventricular myocardium. *Circ Res* 1990;67:615–627. [PubMed: 2397572]
30. Krishnan SC, Antzelevitch C. Sodium channel block produces opposite electrophysiological effects in canine ventricular epicardium and endocardium. *Circ Res* 1991;69:277–291. [PubMed: 1650294]
31. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. *J Am Coll Cardiol* 1996;27:1061–1070. [PubMed: 8609322]
32. Lukas A, Antzelevitch C. Differences in the electrophysiological response of canine ventricular epicardium and endocardium to ischemia: role of the transient outward current. *Circulation* 1993;88:2903–2915. [PubMed: 8252704]
33. Di Diego JM, Sun ZQ, Antzelevitch C. I_{to} and action potential notch are smaller in left vs. right canine ventricular epicardium. *Am J Physiol* 1996;271:H548–H561. [PubMed: 8770096]
34. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. *Circulation*;1999;100:1660–1666.
35. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada Syndrome. *Circulation* 2004;110:1731–1737. [PubMed: 15381640]
36. Alings M, Dekker L, Sadee A, Wilde A. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. *Pacing Clin Electrophysiol* 2001;24(9 pt 1):1420–1422. [PubMed: 11584468]
37. Hermida JS, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P, Guicheney P, Di Fusco S, Rey JL, Cauchemez B, Leenhardt A. Hydroquinidine therapy in Brugada syndrome. *J Am Coll Cardiol* 2004;43:1853–1860. [PubMed: 15145111]